VYJUVEK
Dystrophic Epidermolysis Bullosa
CommercialFDA Approved - First redosable gene therapy
Key Facts
Indication
Dystrophic Epidermolysis Bullosa
Phase
Commercial
Status
FDA Approved - First redosable gene therapy
Company
About Krystal Biotech
Krystal Biotech is a NASDAQ-listed gene therapy company that has successfully transitioned from development to commercial stage with VYJUVEK, their FDA-approved treatment for dystrophic epidermolysis bullosa. Built on a clinically-proven HSV-1 vector platform that is replication-defective and non-integrating, the company focuses on redosable gene therapies for rare genetic diseases. With two GMP manufacturing facilities and global operations spanning the US, Europe, and Japan, Krystal is advancing an extensive pipeline targeting genetic conditions with high unmet medical needs.
View full company profile